Vicore Pharma Holding AB (publ)

VICO · Nasdaq Stockholm · Healthcare

9.32SEK −1.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −30.1%

Performance

1 month

−14.5%

1 year

−30.1%

3 years, per year

−15.3%

5 years, per year

−14.0%

Largest fall, 3 years

−82.9%

Below the peak now

−75.2%

Volatility, 1 year

53.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.0

Dividend yield

0.0%

Return on equity

−58.8%

Net margin

−154.2%

Market value

261 m USD

Quality, value and trend

Where Vicore Pharma Holding stands against every Nordic stock today. 100 is best.

Quality62

Profitability and a sound balance sheet over time. Better than 62% of Nordic stocks.

Value6

The price measured against earnings, assets and cash flow. Better than 6% of Nordic stocks.

Trend15

The price development over the past year. Better than 15% of Nordic stocks.

Combined11

Quality, value and trend together. Better than 11% of Nordic stocks.

About Vicore Pharma Holding

Vicore Pharma Holding AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 46 employees.

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis